Arcus Biosciences (RCUS) Tops Q2 EPS by 18c
Tweet
Share
E-mail
Get Alerts RCUS Hot Sheet
Join SI Premium – FREE
Arcus Biosciences (NYSE: RCUS) reported Q2 EPS of ($0.72), $0.18 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $41 million versus the consensus estimate of $22.22 million.
For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paysign, Inc. (PAYS) Tops Q2 EPS by 5c ; Offers Guidance
- Vir Biotechnology Inc. (VIR) Tops Q2 EPS by 14c
- LifeMD, Inc. (LFMD) Misses Q2 EPS by 6c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
